NCT00241358

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

A Phase I/II Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.

Detailed description

This study will determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.

Conditions

• Leukemia, Myeloid, Acute
• Leukemia, Myelogenous, Chronic
• Leukemia, Lymphoblastic, Acute
• Lymphocytic Leukemia, Chronic
• Myelodysplastic Syndromes
• Multiple Myeloma
• Lymphoma, Non-Hodgkin
• Hodgkin Disease

Interventions

Type	Name	Description
DRUG	AMD3100
PROCEDURE	Stem Cell Transplant

Timeline

• Start date: 2004-05-01
• Primary completion: 2009-12-01
• Completion: 2010-02-01
• First posted: 2005-10-18
• Last updated: 2017-06-06
• Results posted: 2017-06-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study